NSE / BSEHealthcare
β‚Ή2427.25-0.55-0.02%
P/E24.5Mkt Capβ‚Ή28.32 K CrEV/EBITDA17.3

Gland Pharma Limited

P/E24.5Mkt Capβ‚Ή28.32 K CrEV/EBITDA17.3
Company Profile

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 18.32% over 1Y
Monthly Returns

Historically, Jul has averaged the highest return (+8.2%); Oct the lowest (-6.9%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026+7.2%Positive MonthJan 2026: +7.16%-1.2%Neutral MonthFeb 2026: -1.22%-6.9%Negative MonthMar 2026: -6.90%+3.2%Positive MonthApr 2026: +3.16%+33.0%Positive MonthMay 2026: +33.02%+6.6%Positive MonthJun 2026: +6.62%-2.3%*Negative MonthJul 2026: -2.26%β€”β€”β€”β€”β€”
2025-14.2%Negative MonthJan 2025: -14.25%+1.7%Neutral MonthFeb 2025: +1.70%+2.6%Positive MonthMar 2025: +2.56%-12.2%Negative MonthApr 2025: -12.17%+13.6%Positive MonthMay 2025: +13.59%+15.3%Positive MonthJun 2025: +15.34%+12.7%Positive MonthJul 2025: +12.75%-9.6%Negative MonthAug 2025: -9.61%+6.8%Positive MonthSep 2025: +6.76%-3.2%Negative MonthOct 2025: -3.20%-8.8%Negative MonthNov 2025: -8.82%-2.1%Negative MonthDec 2025: -2.11%
2024+1.6%Neutral MonthJan 2024: +1.62%-9.7%Negative MonthFeb 2024: -9.73%+4.4%Positive MonthMar 2024: +4.38%-7.1%Negative MonthApr 2024: -7.08%+7.5%Positive MonthMay 2024: +7.46%-0.8%Neutral MonthJun 2024: -0.80%+17.5%Positive MonthJul 2024: +17.46%-14.2%Negative MonthAug 2024: -14.23%-2.3%Negative MonthSep 2024: -2.34%-8.0%Negative MonthOct 2024: -8.04%+5.3%Positive MonthNov 2024: +5.35%+2.4%Positive MonthDec 2024: +2.35%
2023-17.5%Negative MonthJan 2023: -17.51%+1.3%Neutral MonthFeb 2023: +1.30%-3.7%Negative MonthMar 2023: -3.68%+7.1%Positive MonthApr 2023: +7.11%-32.1%Negative MonthMay 2023: -32.06%+15.1%Positive MonthJun 2023: +15.12%+21.8%Positive MonthJul 2023: +21.77%+34.3%Positive MonthAug 2023: +34.34%-3.7%Negative MonthSep 2023: -3.65%-7.7%Negative MonthOct 2023: -7.67%+14.7%Positive MonthNov 2023: +14.71%+8.4%Positive MonthDec 2023: +8.43%
2022-11.3%Negative MonthJan 2022: -11.27%-4.9%Negative MonthFeb 2022: -4.86%+0.3%Neutral MonthMar 2022: +0.26%-2.0%Negative MonthApr 2022: -2.01%-10.7%Negative MonthMay 2022: -10.69%-5.6%Negative MonthJun 2022: -5.56%-16.3%Negative MonthJul 2022: -16.34%+4.8%Positive MonthAug 2022: +4.76%-11.5%Negative MonthSep 2022: -11.52%-14.8%Negative MonthOct 2022: -14.83%-0.4%Neutral MonthNov 2022: -0.40%-11.3%Negative MonthDec 2022: -11.33%
2021β€”β€”β€”β€”β€”+8.4%Positive MonthJun 2021: +8.38%+15.5%Positive MonthJul 2021: +15.53%-1.4%Neutral MonthAug 2021: -1.43%-4.2%Negative MonthSep 2021: -4.17%-1.0%Neutral MonthOct 2021: -0.98%-3.0%Negative MonthNov 2021: -3.02%+7.8%Positive MonthDec 2021: +7.84%
AvgΒ±SD-6.8%Β±9.5%-2.6%Β±4.3%-0.7%Β±4.1%-2.2%Β±6.9%+2.3%Β±22.1%+6.5%Β±7.7%+8.2%Β±13.3%+2.8%Β±17.1%-3.0%Β±5.8%-6.9%Β±4.8%+1.6%Β±8.0%+1.0%Β±7.3%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.409x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή4.12 K Crβ–Ό 1.2%
EBITDA Growthβ€”
Net Profitβ‚Ή1.09 K Crβ–² 4.5%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 229.5%
Revenue CAGR 5Y9.6%
EBITDA CAGR 5Y7.6%
Net Profit CAGR 5Y6.2%
NP Growth 1Y4.5%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή4.12 K Crβ€”β‚Ή1.09 K Crβ€”β€”11.2%-1.2%4.5%
Mar 2024β‚Ή4.17 K Crβ€”β‚Ή1.04 K Crβ€”β€”11.6%15.2%34.4%
Mar 2023β‚Ή3.62 K Crβ€”β‚Ή776.00 Crβ€”β€”9.8%-17.8%-36.0%
Mar 2022β‚Ή4.40 K Crβ€”β‚Ή1.21 K Crβ€”β€”16.9%27.1%21.6%
Mar 2021β‚Ή3.46 K Crβ€”β‚Ή997.00 Crβ€”β€”16.9%31.5%29.0%
Mar 2020β‚Ή2.63 K Crβ€”β‚Ή773.00 Crβ€”β€”21.2%28.8%71.0%
Mar 2019β‚Ή2.04 K Crβ€”β‚Ή452.00 Crβ€”β€”15.8%26.2%40.8%
Mar 2018β‚Ή1.62 K Crβ€”β‚Ή321.00 Crβ€”β€”13.3%9.5%-22.5%
Mar 2017β‚Ή1.48 K Crβ€”β‚Ή414.00 Crβ€”β€”19.8%9.7%31.8%
Mar 2016β‚Ή1.35 K Crβ€”β‚Ή314.00 Crβ€”β€”18.7%35.6%50.2%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales9919941,3481,4791,6202,0442,6333,4634,4013,6174,1674,1164,154
Total Expenses6306788458541,0851,3381,6782,1612,8902,5982,7582,6742,635
EBIT / Operating Profit3613165026255357069551,3021,5111,0191,4101,4431,519
OPM %36%32%37%42%33%35%36%38%34%28%34%35%37%
Other Income93037344966139135224184166215246
Finance Costs131716644735782333
Depreciation & Amortisation2857637478829599110147162169175
Profit Before Tax3272724595785026869931,3351,6191,0481,4051,4661,557
Tax %32%23%32%28%36%34%22%25%25%26%26%26%-
Net Profit / PAT2242093144143214527739971,2127761,0431,0901,156
EPS (β‚Ή)190.40133.53202.40267.01207.24291.6549.8860.9473.7847.1163.3466.1470.18
Dividend Payout %0%0%0%0%0%0%0%0%0%0%32%27%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Gland Pharma Limitedthis co.β‚Ή28.32 K Crβ‚Ή4.12 K Cr24.502.8217.29-1.2%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Gland Pharma Limited and the metrics that matter.

Browse the full Equiscale Academy